Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 19, Art. 35 (pp. 468-484)    |    2018       

»

Intraoperative reveal of uterine leiomyosarcoma a clinical case and review

B.L. Tsivyan 1, 2, E.V. Konstantinova1, S.V. Vardanyan1,2, S.B.Onegova 1

1 City Hospital No 40, Sestroretsk, Russia;
2 North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russia

Brief summary

Uterine leiomyosarcoma is a rare neoplasm of the uterine body. It accounts for only 1-2 % of malignant tumors of the uterus. Suffer from leiomyosarcoma, according to the authors, more women over 50 years. Leiomyosarcoma is known for the aggressive nature of the course and the poor prognosis of the disease. Diagnosis of this tumor is quite difficult, and often in the initial stages of the disease is not possible, since there are no pathognomonic signs of the disease and technologies for its detection. Leiomyosarcoma is extremely rarely detected before and during surgery and often becomes a finding during the investigation of histological specimen. Rare occurrence of the tumor complicates its diagnosis and the development of new techniques for its detection. This article is devoted to description of private experience intraoperative detection of uterine leiomyosarcoma in patient 48 years old with uterine myoma.


Key words

leiomyosarcoma, myoma uteri, hysterectomy

Reference list

1. Bogani G. Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis./ Bogani G. Cliby W.A., Aletti G.D. // Gynecol Oncol. - 2015. Vol. 137. - P.167-172.


2. Prakticheskie rekomendacii po lecheniu raka tela matki i sarkom matki / Nechyshkina V.M., Dengina N.V., Kolomiec L.A., Kravec O.A., Morohov K.U., Novikova E.G. i soavt. // Zlokachestvennie opyholi: Prakticheskie rekomendacii RUSSCO N3.2. - 2018. - T.8. - S.190-203.


3. Hinchcliff E..M The role of endometrial biopsy in the preoperative detection of uterine leiomyosarcoma. / Hinchcliff E..M., Esselen K.M., Watkins J.C., Oduyebo T., Rauh‐Hain J.A., Del Carmen M.G., et?al. // J Minim Invasive Gynecol - 2016. Vol.23. - P. 567-72.


4. Kawamura N. Transcervical needle biopsy for the differential diagnosis between uterine sarcoma and leiomyoma. / Kawamura N., Ichimura T., Ito F., Shibata S., Takahashi K., Tsujimura A., et al. // Cancer. - 2002. Vol. 94. - P.1713-20.


5. Tamura R. Preoperative ultrasoundguided needle biopsy of 63 uterine tumors having high signal intensity upon T2-weighted magnetic resonance imaging. / Tamura R., Kashima K., Asatani M., et al. // Int J Gynecol Cancer. - 2014. Vol.24. - P.1042-1047.


6. Amant F. Clinical management of uterine sarcomas. / Amant F., Coosemans A., Debiec‐Rychter M., Timmerman D., Vergote I.// Lancet Oncol. - 2009. Vol.10. - P.1188-98.


7. Cornfeld D. MRI appearance of mesenchymal tumors of the uterus./ Cornfeld D., Israel G., Martel M., Weinreb J., Schwartz P., McCarthy S. // Eur J Radiol. - 2010. Vol.74 - P.241-9.


8. Lin G. Comparison of the diagnostic accuracy of contrast‐enhanced MRI and diffusion‐weighted MRI in the differentiation between uterine leiomyosarcoma/smooth muscle tumor with uncertain malignant potential and benign leiomyoma. / Lin G., Yang L.Y., Huang Y.T., Ng K.K., Ng S.H., Ueng S.H., et?al.// J Magn Reson Imaging. - 2016. Vol. 43. - P.333-42


9. Umesaki N. Positive emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging. / Umesaki N., Tanaka T., Miyama M., et al. // Gynecol Oncol. - 2001. Vol.80. - P.372 -377.


10. Wood L.N. Public Awareness of Uterine Power Morcellation Through US Food and Drug Administration Communications: Analysis of Google Trends Search Term Patterns. / Wood L.N., Jamnagerwalla J., Markowitz M.A., Thum D.J., McCarty P., Medendorp A.R., Raz S., Kim J.H. // JMIR Public Health Surveill. - 2018. Vol. 4(2). - P. 47. DOI: 10.2196/publichealth.9913


11. Wright J.D. Trends in Use and Outcomes of Women Undergoing Hysterectomy With Electric Power Morcellation. / Wright J.D., Chen L., Burke W.M., Hou J.Y., Tergas A.I., Ananth C.V., Hershman D.L. // JAMA. - 2016. Vol.316 (8). - P. 877-8.


12. Mioma matki: klinicheskie rekomendacii (protokol lecheniya). - M.: Minzdrav RF, 2015g.


13. Corcoran S. Isolated cutaneous metastasis of uterine leiomyosarcoma: Case report and review of literature./ Corcoran S., Hogan A.M., Nemeth T., Bennani F., Sullivan F.J., Khan W., et al.// Diagn Pathol. - 2012. Vol.7. - P.85.


14. Perri T. Uterine leiomyosarcoma: does the primary surgical procedure matter? / Perri T., Korach J., Sadetzki S., Oberman B., Fridman E., Ben-Baruch G. // Int J Gynecol Cancer. - 2009. Vol.19. - P. 257-260.


15. Gockley A.A. Uterine leiomyosarcoma: a review article./ Gockley A.A., Rauh‐Hain J.A., del Carmen M.G. // Int J Gynecol Cancer. - 2014. Vol.;24 - P.1538-42.


16. Wickerham D.L. Association of tamoxifen and uterine sarcoma. / Wickerham D.L., Fisher B., Wolmark N., et al. // J Clin Oncol. - 2002. Vol. 20. - P.2758-2760.


17. Papadia A. Uterine sarcoma occurring in a premenopausal patient after uterine artery embolization: a case report and review of the literature. / Papadia A., Salom E.M., Fulcheri E., Ragni N. // Gynecol Oncol. - 2007. Vol.104. - P. 260-263.


18. AAGLAdvancing Minimally Invasive Gynecology Worldwide. AAGL practice report: Morcellation during uterine tissue extraction. // J Minim Invasive Gynecol. - 2014. Vol.21 - P. 517-530.


19. Pelmus M. Prognostic factors in early-stage leiomyosarcoma of the uterus./ Pelmus M., Penault-Llorca F., Guillou L., Collin F., Bertrand G., Trassard M., Leroux A., Floquet A., Stoeckle E., Thomas L., MacGrogan G. // Int J Gynecol Cancer. - 2009. Vol.19. - P. 385-390.


20. Lee E.J. Profiling of differentially expressed genes in human uterine leiomyomas. / Lee E.J., Kong G., Lee S.H., Rho S.B., Park C.S., Kim B.G., et al. // Int J Gynecol Cancer. 2005. Vol.15. - P.146-54.


21. Quade B.J. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. / Quade B.J., Wang T.Y., Sornberger K., Dal Cin P., Mutter G.L., Morton C.C. // Genes Chromosomes Cancer. - 2004. Vol.40. - P.97-108.


22. Leibsohn S. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. / Leibsohn S., d?Ablaing G., Mishell Jr. D.R. et al. // Am J Obstet Gynecol. 1990. Vol. 162. - P. 968-974. Dis. 74-76.


23. Zhang P. Use of X-chromosome inactivation pattern to determine the clonal origins of uterine leiomyoma and leiomyosarcoma. / Zhang P., Zhang C., Hao J. et al. // Hum Pathol. - 2006. Vol. 37. - P. 1350-1356.


24. IJGO. - 2009. Vol. 105. - P. 3-4; IJGO. - 2009. Vol. 104. - P. 179


25. Prakticheskie rekomendacii po lekarstvennomy lecheniu raka tela matki i sarkom matki / Hohlova S. V., Kolomiec L. A., Kravec O. A., Krikynova L. I., Nechyshkina V. M., Novikova E. G. i soavt. // Zlokachestvennie opyholi. - 2016. - N 4. Specvipysk 2. - S. 161-175


26. Si M. Role of lymphadenectomy for uterine sarcoma: a meta‐analysis. / Si M., Jia L., Song K., Zhang Q., Kong B. // Int J Gynecol Cancer. - 2017. Vol.27. - P.109-116.


27. Brohl A.S. Age‐stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. / Brohl A.S., Li L., Andikyan V., Obican S.G., Cioffi A., Hao K., et al. // Oncologist. - 2015. Vol.20 - P.433-9.


28. Reed N.S. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874) / Reed N.S., Mangioni C., Malmstrom H., Scarfone G., Poveda A., Pecorelli S., et?al. // Eur J Cancer. - 2008. Vol.44. - P. 808 -18.


29. Sampath S. Role of radiotherapy treatment of uterine sarcoma./ Sampath S., Gaffney D.K. // Best Pract Res Clin Obstet Gynaecol. - 2011. Vol. 25. - P.761-72.


30. Bogani G. Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: a systematic review and meta‐analysis. / Bogani G., Fuca G., Maltese G., Ditto A., Martinelli F., Signorelli M., et?al. // Gynecol. Oncol. - 2016. Vol.143. - P.443-7.


31. Maki R.G. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 (corrected). / Maki R.G., Wathen J.K., Patel S.R., Priebat D.A., Okuno S.H., Samuels B., et?al. // J Clin Oncol. - 2007. Vol.25. - P.2755-63.


32. Reichardt P. The treatment of uterine sarcomas. //Ann Oncol. - 2012. Vol. 23(Suppl 10). - P. 151-7.


33. Hensley M.L. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first‐line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology. Gynecologic Oncology Group study./ Hensley M.L., Miller A., O'Malley D.M., Mannel R.S., Behbakht K., Bakkum‐Gamez J.N., et?al. // J Clin Oncol. - 2015. Vol.33. - P.1180-5.


34. Ioffe Y.J. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles./ Ioffe Y.J., Li A.J., Walsh C.S., Karlan B.Y., Leuchter R., Forscher C., et?al. // Gynecol Oncol. - 2009. Vol.115. - P.466-71.


35. George S. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcoma expressing estrogen and/or progesterone receptors. / George S., Feng Y., Manola J., Nucci M.R., Butrynski J., Morgan J. // Cancer. - 2014. Vol. 120. - P. 738-43.


36. Zhang P. Epigenetic regulators: new therapeutic targets for soft tissue sarcoma. / Zhang P., Pollock R.E. // Cancer Cell Microenviron. - 2014. Vol.1. - P.191


37. Hosh M. Uterine sarcoma: analysis of 13,089 cases based on surveillance, epidemiology, and end results database. / Hosh M., Antar S., Nazzal A., Warda M., Gibreel A., Refky B. // Int J Gynecol Cancer. - 2016. Vol.26. - P.1098-104.


38. Ann M.S. Characterization and Preoperative Risk Analysis of Leiomyosarcomas at a High-Volume Tertiary Care Center Peters / Ann M.S., Sadecky A. M., Winger D. G., Guido R. S., Lee T.M., Mansuria S. M., Donnellan N. M. // International Journal of Gynecological Cancer. - 2017. Vol. 27 (Issue 6). - P.1183-1190. doi: 10.1097/IGC.0000000000000940


39. Wolfson A.H. A multivariate analysis of clinicopathologis factors for predicting outcome in uterine sarcomas. / Wolfson A.H, Wolfson D.J., Sittler S.Y., Breton L., Markoe A.M., Schwade J.G., Houdek P.V., Averette H.E., Sevin B.U., Penalver M. // Gynecol Oncol. - 1994. Vol. 52. - P.56-62.